stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) EV/FCF
As of 5 November 2026, Palvella Therapeutics, Inc. (PVLA) trades at a EV/FCF of −62.4×. Over the past ten years it has ranged from −78.4× (February 2026) to 117× (October 2018); the current reading is higher than 2% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2023 | −1.5× | — |
| FY2022 | −0.4× | — |
| FY2021 | −14.8× | — |
| FY2020 | −1.4× | — |
| FY2019 | −1.5× | — |
| FY2018 | −5.2× | — |
| FY2017 | 5.6× | — |
| FY2016 | −2.2× | — |
| FY2015 | −3.8× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Mar 2024 | −0.2× | — |
| Dec 2023 | −1.5× | — |
| Sep 2023 | 0.3× | (61.48%) |
| Jun 2023 | 0.8× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. | −62.4× |
| PHVS Pharvaris N.V. compare | −10.5× |
| IMNM Immunome, Inc. compare | −7.0× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| AUPH Aurinia Pharmaceuticals Inc compare | 9.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement